Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey guys,
I haven’t been here since the TAU flop. Been poking around. Market makers piss me off in OTC. I literally slapped the ask twice With a small buy in and my ask dosen’t fill and then the ask jumps a couple points. I assume this is manipulated by the MM’s. Do any of y’all have a better understanding of why this is?
Thanks for the reply. Everyone needs to do their DD and use the information in the PR’s to determine the news.
Help me understand this math.
136 were given Zyesami, while 67 were SOC.
Based on the numbers given in surviving at 28 days .67% survived taking Zyesami while .70% survived on SOC.
As for the ones released by 28 days .48% were released on Zyesami while .46% on SOC were released.
I don’t see where the huge upside is here. Am I figuring this wrong?? If so how??
AXXA squires Swiss med supply company
https://www.prnewswire.com/news-releases/exxe-group-acquires-fast-growing-swiss-medical-supply-company-301145696.html
“The largest manufacturers of inhalers are GlaxoSmithKline (makers of the Advair Diskus and Flixotide), Merck (makers of Asmanex and Proventil HFA), AstraZeneca (makers of Pulmicort and Symbicort) and Boehringer-Ingelheim (makers of Atrovent, Combivent, and Spiriva which are used for asthma, COPD, and emphysema)”
Wonder one it could be????
“Data from the clinical trials are expected by the end of August.”
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
I’ve googled it and it looks like 3 weeks roughly. I’d like to think this one would get expedited since it seriously is a life and death issue.
If they get approval for this drug and it does what it has shown to do in the few studies we have at the moment there will be no need to RS.
I’m sure this point may have already been posted but these guys were happy with a 35% success rate.
We are near 100% on the worst case scenario patients out there. Let that sink in.
Now, do I believe the stock is about to fly over a dollar?? Not Unless something very positive and news worthy pops like another series of articles in the NYT, NYP, and Reuters, or the partnership announcements, or the phase study conclusion coming up very soon, and the peer reviewed study release.
We are sitting pretty in the short term but immediate term may be a little bumpy. I’m holding a lot of shares for me and will be holding until we are way into dollars. It may take a few weeks longer than I want or it may start rolling out this week. Either way I’m holding tight even if it gets bumpy.
Hopefully news will continue to spread and more hospitals will use RLF-100 for compassionate use while we await approval from the FDA. If we can clean out a few ICU’s and make some waves we will get the press release we want from the Trumpmister
https://video.foxnews.com/v/6183789502001#sp=show-clips
The Fox News link fir anyone who wants to watch
New York Times, New York Post, Reuter’s, and Fox News Busines all carried stories in this in the last couple weeks. You better believe follow ups are about to rollout when the peer review hits.
It’s may take a few more news pushes to get this where we all want it to go. I have no doubt that it will get there soon. However right now we are still restricted our base group of fanatics (like myself), flippers, traders, and shorts. When this pops out in the peer reviewed journal, and the major news sites start picking it up again, and.... the trial results are released, and.... the partnerships are announced, and..... we start emptying ICU’s across the nation/world we are going to fly. We are very close, within weeks. There’s no other drug that has done what this has done. It’s just not out there. We may have a few slow days and some dips before the big push comes. But how many stocks have there ever been that had this much news prior to blowing the roof with PROVEN success??? Not many I can tell you that. Be patient and get ready.
“The manuscript has been submitted for peer review to a leading scientific journal.”
https://relieftherapeutics.com/relief-therapeutics-and-neurorx-note-submission-of-clinical-results-from-21-patient-study-for-publication/
I’ve have a ton of cheep shares. I was just looking To trade an extra 20k shares while I hold my ton on the side ????. I hate when the bid keeps moving around no matter what I do. They are trying to force you to his the ask. It’s manipulation and I’ve seen it before
Absolute manipulation!!!! I tired to buy the dip and every time I bunked my bid it would move up a fraction of a penny over my bid. I’d move it down and it would likewise follow. Total BS
Good morning Team,
Myself along with others sent out a first draft copy of RLFTF’s study in 21 patients. The one below is the actual paper that went out this morning. There are several important updates and clarifications. The news is “Striking” as noted in the paper.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
If you are interested in this stock you need to read this paper. If you are ready to invest in other stocks that will rise when we get a Covid treatment that will get the economy back to full throttle you may be looking at it right here. The paper makes note that this
Drug has shown in the past and may in the future be used for all sorts of other pulmonary issues. I am so very pleased with this outcome. Here are some excerpts.
“Comment: The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.”
“Clinical Results
Median patient follow-up time is 21 days. So far, 19 of 21 patients have survived. One death was due to COVID-related multisystem organ failure and the other (on ECMO) to an underlying and unrelated encephalopathy.
Twenty of 21 patients demonstrated improvement in blood oxygenation (Fig 1). The improvement in patients on ECOM was similar to that seen in patients treated with conventional mechanical ventilation. Available data from blood gases showed stark increases in PaO2:FiO2 ratio after the 2nd dose (Median increase = 92.5, IQR = 74) and at 24 hours after the 3rd dose (Median increase over baseline 84.5, IQR = 110). No patient showed deterioration of oxygenation below baseline during subsequent measurements.
Radiographic evidence (Fig 2) on all patients is included in the online supplementary material. Full or partial resolution of the “ground glass” parenchymal changes associated with COVID-19”
“The significant clinical improvement seen in these 21 patients treated with intravenous RLF-100TM (aviptadil), is consistent with the finding that VIP both blocks viral replication in pulmonary ATII and creates a “bystander effect” whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. The rapidity and magnitude of clinical effect has not been reported to our knowledge in association with any other COVID-19 therapeutic agent, suggesting a highly specific role of VIP in combating the lethal effects of SARS-CoV-2 infection.”
“The clinical course of the patients in this study, with some having demonstrated rapid clinical recovery and discharge to home while others continue to improve more slowly, is striking for the consistency of improvement on radiographic changes, blood levels of inflammatory markers, and improvement in blood oxygenation. The radiographic improvement seen in these patients, is highly atypical for COVID-19 and suggests that aviptadil may be effective in treating COVID-19 and has substantial potential to demonstrate efficacy in adequately-controlled trials.”
“Aviptadil may have further value as a nasopharyngeal drug to prevent SARS-CoV-2 from successfully infecting nasopharyngeal cells and starting the pathogenic process of COVID-19. Moreover, aviptadil may have promise in treating a broad array of pulmonary inflammatory conditions.”
It may take a little time to get this main stream but we should see and hear much more in the following weeks. The biggest take away is that this study was on the worst of the worst patients. Imagine the trial results in folks that are generally healthy and not in need of ventilation and ECMO. I really think we have found the best therapeutic for this pandemic.
Maybe they will buy them out for 15-20 per share ????????
My phone does not download this. What it the sort version of what you found
How many folks were actually trading and hunting good news late on a Wednesday besides us degenerates?? This will marinate all nite, Reuters, NYP, and NYT will follow you with articles, Fox business will invite back to the show, DR Phil will be tweeting shortly. We will likely have official PR’s, it will not be long before Trump starts doubling down on this.
“Moreover, the DMC has determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil and placebo in remission from COVID-19 respiratory failure.”
In the conclusion of the document
Swiss marker will explode tomorrow right before we do!!!!
“Radiographic evidence (figure 2) on all patients is included in the online supplementary material. In all cases, clearing of the “ground glass” parenchymal changes associated with COVID-19 pneumonitis was apparent and was noted by the radiologists who read the chest x-rays. Quantitative analysis of radiographic changes will be the subject of a future report.”
Average age of the 21 patients was 71yr old. This gives me great hope that our fire fighter will get off ECMO!!!!!!!
Sticky this link !!!!
Imgur shots of the report!!!
https://imgur.com/gallery/Y5eq572
Houston Methodist releases bomb shell news on RLF-100.
Another Hospital north of Houston rushes RLF-100 over to help a severely sick Covid patient
A hospital in south Texas signs up to use RLF-100.
Question..... do you think the Hospital in South Texas read about RLF-100 in the news?? Or do you think they are talking among themselves about the actual results????
We have no way to know for sure but I’m leaning on this is being talked about between staff between locations which is why Interest is growing.
For those that haven’t seen yet.
Looks like that Firefighter got the RLF-100. Let pray this works for Him.
https://imgur.com/gallery/fqVVu5Z
Alrighty flippers better hurry and amass those shares before the power hour run!!!
Why would a Dr. be invited back to his Princeton Alma Mater to report on a failed effort on a failed Drug????
I wonder how much of this run is due to the same Alma Mater’s friends and families taking position????
Great find!!!
Swiss market enters their power hour in 5mins
https://infomeddnews.com/relief-therapeutics-holding-sa-announces-plans-to-test-aviptadil-for-treatment-of-covid-induced-acute-respiratory-distress-syndrome/
“The State of Israel is eager to test this potentially lifesaving treatment in patients who today have no other therapeutic option, said Dr. Halberthal. We will try every possible mechanism to help safeguard our patients in this global crisis.”
“we intend to initiate phase 2 clinical trials on an urgent schedule in order to bring a potentially life-saving drug to patients.”
Great that means we will get results that much sooner!!! Thanks for pointing out !!!
Buy the rumor sell the news. We are still in the rumor phase so it’s buy time and all indicators point towards monumental news. Win win
There’s no telling the news sources that will be running this all weekend. Monday could be record setting
RLFTF — Reuters News
Looks like all the major news outlets will be keeping tabs on this drug. Free PR!!! Wait until this hits Fox, NBC, and CNN!!!
https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKCN2520ED